Further Strategies for Treating Fibromyalgia: The Role of Serotonin and Norepinephrine Reuptake Inhibitors

American Journal of Medicine

Volumn 122, Issue 12 SUPPL., 2009, Pages

  Mease, Philip J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Dual reuptake inhibitor; Duloxetine; Fibromyalgia; Milnacipran; Norepinephrine; Serotonin

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; CYCLOBENZAPRINE; DESIPRAMINE; DOSULEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MILNACIPRAN; MOCLOBEMIDE; NORADRENALIN; NORADRENALIN TRANSPORTER; NORTRIPTYLINE; PAROXETINE; PLACEBO; S ADENOSYLMETHIONINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL PAIN; ANALGESIC ACTIVITY; ANOREXIA; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHRONIC FATIGUE SYNDROME; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DISEASE MODEL; DNA POLYMORPHISM; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; GENETIC TRANSCRIPTION; HEART RATE; HUMAN; IRRITABLE COLON; LOW DRUG DOSE; MAJOR DEPRESSION; NAUSEA; NEUROMODULATION; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PAIN ASSESSMENT; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SEDATION; SEROTONIN BLOOD LEVEL; SIDE EFFECT; TEMPOROMANDIBULAR JOINT DISORDER; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION; XEROSTOMIA;

ANALGESICS; ANIMALS; DISEASE MODELS, ANIMAL; FIBROMYALGIA; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PAIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 70749118211     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.09.010     Document Type: Article

References (72)

1. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 75 (2005) 6-21
2. Yunus M.B. Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain. Best Pract Res Clin Rheumatol 21 (2007) 481-497
3. Lautenbacher S., Rollman G.B., and McCain G.A. Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. Pain 59 (1994) 45-53
4. Gracely R.H., Petzke F., Wolf J.M., and Clauw D.J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46 (2002) 1333-1343
5. Staud R., and Rodriguez M.E. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol 2 (2006) 90-98
6. Houvenagel E., Forzy G., Leloire O., et al. Cerebrospinal fluid monoamines in primary fibromyalgia [in French]. Rev Rhum Mal Osteoartic 57 (1990) 21-23
7. Russell I.J., Vaerøy H., Javors M., and Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35 (1992) 550-556
8. Staud R. Predictors of clinical pain intensity in patients with fibromyalgia syndrome. Curr Pain Headache Rep 9 (2005) 316-321
9. Fields H.L., Heinricher M.M., and Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 14 (1991) 219-245
10. Kranzler J.D., Gendreau J.F., and Rao S.G. The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull 36 (2002) 165-213
11. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol 19 suppl 1 (2004) S15-S19
12. Arnold L.M., Lu Y., Crofford L.J., et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50 (2004) 2974-2984
13. Arnold L.M., Rosen A., Pritchett Y.L., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119 (2005) 5-15
14. Russell I.J., Mease P.J., Smith T.R., et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136 (2008) 432-444
15. Gendreau R.M., Thorn M.D., Gendreau J.F., et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32 (2005) 1975-1985
16. Mease P.J., Clauw D.J., Gendreau R.M., et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial [published correction appears in J Rheumatol 2009;36:661]. J Rheumatol 36 (2009) 389-409
17. Clauw D.J., Mease P., Palmer R.H., Gendreau R.M., and Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial [published correction appears in Clin Ther 2009;31:446]. Clin Ther 30 (2008) 1988-2004
18. Branco J.C., Zachrisson O., Perrot S., et al. A European, multicenter, randomized, double-blind, placebo-controlled monotherapy clinical trial of milnacipran in the treatment of fibromyalgia. J Rheumatol (2009) In press
19. Clauw D.J. Fibromyalgia: an overview. Am J Med 122 suppl (2009) S3-S13
20. Bradley L.A. Pathophysiology of fibromyalgia. Am J Med 122 suppl (2009) S22-S30
21. Stratz T., Samborski W., Hrycaj P., et al. Serotonin concentration in serum of patients with generalized tendomyopathy (fibromyalgia) and chronic polyarthritis [in German]. Med Klin (Munich) 88 (1993) 458-462
22. Yunus M.B., Dailey J.W., Aldag J.C., Masi A.T., and Jobe P.C. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 19 (1992) 90-94
23. Wolfe F., Russell I.J., Vipraio G., Ross K., and Anderson J. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol 24 (1997) 555-559
24. Rao S.G., Gendreau J.F., and Kranzler J.D. Understanding the fibromyalgia syndrome. Psychopharmacol Bull 40 (2007) 24-67
25. Owens M.J., and Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40 (1994) 288-295
26. Offenbaecher M., Bondy B., de Jonge S., et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 42 (1999) 2482-2488
27. Gursoy S. Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of fibromyalgia patients. Clin Rheumatol 21 (2002) 194-197
28. Jones C.K., Eastwood B.J., Need A.B., and Shannon H.E. Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition. Neuropharmacology 51 (2006) 1172-1180
29. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 32 (2000) 305-316
30. Arnold L.M., Keck Jr. P.E., and Welge J.A. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 41 (2000) 104-113
31. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283 (1997) 1305-1322
32. Vaishnavi S.N., Nemeroff C.B., Plott S.J., Rao S.G., Kranzler J., and Owens M.J. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 55 (2004) 320-322
33. Owens M.J., Knight D.L., and Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50 (2001) 345-350
34. Savella [package insert] (2009), Forest Pharmaceuticals, Inc, St. Louis, MO
35. Puozzo C., Panconi E., and Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 17 suppl 1 (2002) S25-S35
36. O'Malley P.G., Balden E., Tomkins G., Santoro J., Kroenke K., and Jackson J.L. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 15 (2000) 659-666
37. Collins S.L., Moore R.A., McQuay H.J., and Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 20 (2000) 449-458
38. Lynch M.E. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 26 (2001) 30-36
39. Jung A.C., Staiger T., and Sullivan M. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med 12 (1997) 384-389
40. Tofferi J.K., Jackson J.L., and O'Malley P.G. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum 51 (2004) 9-13
41. Häuser W., Bernardy K., Uceyler N., and Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 301 (2009) 198-209
42. Staud R. Treatment of fibromyalgia and its symptoms. Expert Opin Pharmacother 8 (2007) 1629-1642
43. Beliles K., and Stoudemire A. Psychopharmacologic treatment of depression in the medically ill. Psychosomatics 39 (1998) S2-S19
44. Goldenberg D.L. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol 21 (2007) 499-511
45. Arnold L.M. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med 8 (2007) S63-S74
46. Harvey A.T., Rudolph R.L., and Preskorn S.H. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57 (2000) 503-509
47. Sayar K., Aksu G., Ak I., and Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 37 (2003) 1561-1565
48. Dwight M.M., Arnold L.M., O'Brien H., Metzger R., Morris-Park E., and Keck Jr. P.E. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 39 (1998) 14-17
49. Zijlstra T.R., Barendregt P.J., and van de Laar M.A.F. Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial [abstract]. Arthritis Rheum 46 suppl (2002) S105
50. Cymbalta [package insert] (2008), Eli Lilly and Company, Indianapolis, IN
51. Chappell A.S., Bradley L.A., Wiltse C., Detke M.J., D'Souza D.N., and Spaeth M. A six-month double-blind, placebo-controlled, randomized trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 1 (2008) 91-102
52. Arnold L.M., Pritchett Y.L., D'Souza D.N., Kajdasz D.K., Iyengar S., and Wernicke J.F. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health 16 (2007) 1145-1156
53. Wise T.N., Perahia D.G., Pangallo B.A., Losin W.G., and Wiltse C.G. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry 8 (2006) 269-278
54. Study of Milnacipran for the Treatment of Fibromyalgia. [ClinicalTrials.gov Website.]. http://clinicaltrials.gov/ct2/show/NCT00314249 Accessed March 20, 2009
55. Mease P.J. Milnacipran: a new treatment option for fibromyalgia. Practical Pain Management (2009; May) 52-57
56. Dionne R.A., Bartoshuk L., Mogil J., and Witter J. Individual responder analyses for pain: does one pain scale fit all?. Trends Pharmacol Sci 26 (2005) 125-130
57. Stahl S.M., Grady M.M., Moret C., and Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10 (2005) 732-747
58. Goldenberg D.L., Clauw D.J., Palmer R.H., Mease P., Chen W., and Gendreau R.M. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med (2009) In press
59. Pae C.U., Masand P.S., Ajwani N., Lee C., and Patkar A.A. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56 (2007) 1770-1798
60. Pae C.U., Masand P.S., Ajwani N., Lee C., and Patkar A.A. Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. Int J Clin Pract 61 (2007) 1708-1718
61. Drossman D.A., Toner B.B., Whitehead W.E., et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125 (2003) 19-31
62. Abdul-Baki H., El Zahabi L.M.N., El Hajj I.I., et al. A randomized double-blind placebo-controlled trial of imipramine in patients with irritable bowel syndrome [abstract]. Am J Gastroenterol 101 (2006) S479
63. Quartero A.O., Meineche-Schmidt V., Muris J., Rubin G., and de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2 (2005) CD003460
64. Jackson J.L., O'Malley P.G., and Kroenke K. Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectr 11 (2006) 212-222
65. Saad R.J., and Chey W.D. Recent developments in the therapy of irritable bowel syndrome. Expert Opin Investig Drugs 17 (2008) 117-130
66. Comparison of Psychological and Pharmacological Treatments of Pain Due to TMD. [ClinicalTrials.gov Website.]. http://clinicaltrials.gov/ct2/show/NCT00066937 Accessed March 20, 2009
67. Goodnick P.J. Treatment of chronic fatigue syndrome with venlafaxine. Am J Psychiatry 153 (1996) 294
68. Toyofuku A., and Miyako H. A case of temporo-mandibular disorder with fibromyalgia treated with the antidepressant, milnacipran. Hum Psychopharmacol 19 (2004) 357-358
69. Rosenhagen M.C., Schmidt U., Ebinger M., Nickel T., and Uhr M. Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine--a case study. J Clin Psychopharmacol 28 (2008) 105-107
70. Double-blind Trial of Duloxetine in Chronic Fatigue Syndrome. [ClinicalTrials.gov Website.]. http://clinicaltrials.gov/ct2/show/NCT00375973 Accessed March 20, 2009
71. An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome. [ClinicalTrials.gov Website.]. http://clinicaltrials.gov/ct2/show/NCT00401258 Accessed March 20, 2009
72. Krell H.V., Leuchter A.F., Cook I.A., and Abrams M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics 46 (2005) 379-384